Showing results (1521-1530 of 1,540) with videos related to
Sort By:
Pageof 154
Nature Communications|December 14, 2017
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemiaXi Jiang, Chao Hu, Kyle Ferchen, et al.Nature Communications|February 11, 2018
Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemiaXi Jiang, Chao Hu, Kyle Ferchen, et al.Bioorganic & Medicinal Chemistry Letters|December 20, 2003
Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridineJin Li, Kristin M Lundy DeMello, Henry Cheng, et al.Journal for Immunotherapy of Cancer|February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinomaThomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.Beilstein Journal of Nanotechnology|November 11, 2014
PVP-coated, negatively charged silver nanoparticles: A multi-center study of their physicochemical characteristics, cell culture and in vivo experimentsSebastian Ahlberg, Alexandra Antonopulos, Jörg Diendorf, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Toward a drug development path that targets metastatic progression in osteosarcomaChand Khanna, Timothy M Fan, Richard Gorlick, et al.Cell|May 3, 2024
Small-molecule-induced epigenetic rejuvenation promotes SREBP condensation and overcomes barriers to CNS myelin regenerationXuezhao Liu, Dazhuan Eric Xin, Xiaowen Zhong, et al.European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug AdministrationAndrew Dj Pearson, Susan Chi, Theodore W Laetscht, et al.Science Translational Medicine|March 9, 2022
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemiaLaura Barreyro, Avery M Sampson, Chiharu Ishikawa, et al.Infection|May 3, 2024
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)Sina M Hopff, Katharina S Appel, Olga Miljukov, et al.Pageof 154